NOTICE OF ALLOWANCE - ISSUED
issued
on 16 Jul 2024
Last Applicant/ Owned by
230 East Grand Avenue, Suite 200
South San Francisco
CA
94080
Serial Number
97697582 filed on 30th Nov 2022
Registration Number
N/A
Correspondent Address
John Paul Oleksiuk
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
TERREMOTO
Drug discovery and development services; computational drug discovery and development services; scientific, medical, biotechnology, biomedical, medicinal chemistry, and pharmaceutical research and development services; scientific and medical testing services in the fields of biotechnology, biomedical, medicinal chemistry, and pharmaceuticals; research, development, discovery and consulting service Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Drug discovery and development services; computational drug discovery and development services; scientific, medical, biotechnology, biomedical, medicinal chemistry, and pharmaceutical research and development services; scientific and medical testing services in the fields of biotechnology, biomedical, medicinal chemistry, and pharmaceuticals; research, development, discovery and consulting services in the fields of biotechnology, biomedical, medicinal chemistry, and pharmaceuticals; research in the fields of chemistry and medicinal chemistry; medical research; clinical research and development services in the fields of biotechnology, biomedical, medicinal chemistry, and pharmaceuticals; medical and scientific research, namely, conducting and evaluating clinical trials for others; providing information about medical and scientific research; providing scientific information in the fields of medicine, biotechnology, medicinal chemistry, and pharmaceuticals; provision of drug discovery and development information; provision of computational drug discovery information;
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; pharmaceuticals for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; pharmaceutical preparations and substances for the prevention and treatment of cancer, oncological diseases, disorders and conditions; pharmaceutical preparations and substances for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; biopharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; biopharmaceuticals for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; medicines for the prevention and treatment of cancer, oncological diseases, disorders and conditions; medicines for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; drugs for the prevention and treatment of cancer, oncological diseases, disorders and conditions; drugs for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; drug compounds for the prevention and treatment of cancer, oncological diseases, disorders and conditions; drug compounds for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; small molecules for the prevention and treatment of cancer, oncological diseases, disorders and conditions; small molecules for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; therapeutics for the prevention and treatment of cancer, oncological diseases, disorders and conditions; therapeutics for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions;
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97697582
Mark Type
No Service Mark
Attorney Docket Number
No 356094-20000
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Design Code(s)
24.15.10 -
More than one arrow
24.15.25 -
Other arrows
26.05.03 -
Incomplete triangles (must have two angles)
26.05.13 -
Two Triangles
26.05.16 -
Triangles touching or intersecting
26.17.01 -
Straight line(s), band(s) or bar(s)
26.17.06 -
Diagonal line(s), band(s) or bar(s)
Legal History
| Status Date | Action Taken |
|---|---|
| 06th Dec 2024 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 06th Dec 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 06th Dec 2024 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 16th Jul 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 03rd Jun 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 03rd Jun 2024 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 03rd Jun 2024 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 21st May 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 21st May 2024 | PUBLISHED FOR OPPOSITION |
| 01st May 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |